Post-Marketing Surveillance Study Emselex.

Trial Profile

Post-Marketing Surveillance Study Emselex.

Phase of Trial: Phase IV

Latest Information Update: 29 Aug 2016

At a glance

  • Drugs Darifenacin (Primary)
  • Indications Overactive bladder
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 06 Jul 2012 New source identified and integrated (German Clinical Trials Register: DRKS00003990).
    • 16 Feb 2009 Additional location (Germany) identified as reported by, last updated 16 Feb 2009.
    • 25 Nov 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top